2023年8月1日 · RBT-1 is a combination drug of stannic protoporfin (SnPP) and iron sucrose (FeS) that elicits a preconditioning response through activation of antioxidant, anti-inflammatory, and iron-scavenging pathways, as measured by heme oxygenase-1 (HO-1), interleukin-10 (IL-10), and ferritin, respectively.

2023年7月11日 · RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways that is advancing toward Phase 3 development for its lead indication to reduce post-operative complications following cardiothoracic surgery.

2024年1月9日 · rbt-1（锡原卟啉/蔗糖铁）是一种固定剂量的组合产品，在手术前24-48小时，在1-2小时内静脉注射一次，是抗炎，抗氧化和铁清除途径的有效诱导剂。 在一项完成的2期研究中，RBT-1在主要和几个临床终点显示出统计学上显着的阳性数据，包括减少ICU时间，缩短患者 ...

2023年7月14日 · RBT-1是Nrf2、IL-10和铁蛋白（ferritin）的强效诱导剂，可诱导细胞保护性预适应（preconditioning）生物标志物（主要来自Nrf2通路）上调，预防心胸手术后的并发症。

2023年7月20日 · Renibus公司的主要项目是RBT-1， 这是一种Nrf2、IL-10和铁蛋白（ferritin）的强效诱导剂， 可诱导细胞保护性预适应生物标志物（主要来自Nrf2通路）上调，预防心胸手术后的并发症。 RBT-1正准备进入3期临床研究阶段，其主要适应症可减少心胸手术的术后并发症。 既往研究表明，细胞保护性预适应生物标志物的上调与动物药理学研究一致，支持了RBT-1的安全性和预适应的临床相关性。 RBT-1的2期研究（NCT04564833）已于2023年2月完成，该研究是一 …

2024年1月8日 · Patients were randomised (1:1:1) to receive either a single intravenous infusion of high-dose RBT-1 (90 mg SnPP/240 mg FeS), low-dose RBT-1 (45 mg SnPP/240 mg FeS), or placebo within 24-48 h before surgery. The primary outcome was a preoperative preconditioning response, measured by a composite of plasma HO-1, IL-10, and ferritin.

2025年2月5日 · RBT-1, a "preconditioning" agent, has been shown to mitigate postoperative complications following cardiac surgeries. This study assessed whether RBT-1 preconditioning attenuated SDC-1 shedding in these patients, implying a vascular protective effect.

2023年7月11日，临床阶段生物制药公司Renibus Therapeutics, Inc.宣布，美国食品药品监督管理局（FDA）授予RBT-1突破性疗法认定，用于降低心胸手术患者术后并发症的风险，并确认其与公司计划中的3期关键试验一致。

2022年6月15日 · RBT-1 is a novel stannous protoporphyrin and iron sucrose fixed-combination agent that induces upregulation of biomarkers of cytoprotective preconditioning, primarily from the...

2023年10月25日 · RBT-1 (stannic protoporfin/iron sucrose), a fixed dose combination product given once intravenously over 1-2 hours, 24-48 hours before surgery, is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways.

2023年7月11日 · RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways that is advancing toward Phase 3 development for its lead...

医药魔方NextPharma®全球新药数据库为您提供「RBT-1 (蔗糖铁+锡原卟啉)」药品的基本信息（药品名称、药品类别、靶点、作用机制、药品简介、研发机构、最高研发阶段、审评审批类型、外置链接）。 了解更多药品相关信息，欢迎申请试用企业版。

RBT-1 is currently under development as a prophy-lactic drug designed to induce a preconditioning response in multiple organs to reduce the hypermeta-bolic consequences of surgery and cardiopulmonary bypass. RBT-1 is a combination drug comprised of stannic protoporfin (SnPP) and iron sucrose (FeS),

2023年7月16日 · RBT-1（SnPP / FeS）是由，Renibus Therapeutics开发的一种有效的Nrf2、IL-10和铁蛋白诱导剂，可诱导细胞保护性预适应（preconditioning）生物标志物（主要来自Nrf2通路）上调，预防心胸手术后的并发症。

2024年4月28日 · RBT-1 is a novel drug comprised of stannic protoporfin and iron sucrose that activates anti-inflammatory and antioxidant pathways and has been shown to improve clinical outcomes after cardiac surgery in a phase 2 trial.

2020年6月6日 · RBT-1 is a novel therapeutic composed of SnPP (tin protoporphyrin) and FeS (iron sucrose) and was designed to induce non-ischemic, oxidant renal preconditioning to prevent AKI. It has shown efficacy in various models of AKI: glycerol-induced (rhabdomyolysis), maleate (ATP depletion), ischemia/reperfusion (I/R), and post-AKI progression to CKD ...

2023年5月7日 · RBT-1 achieved the primary biomarker endpoint, as well as several key clinical outcome endpoints; positive data supports the potential for RBT-1 to improve postoperative outcomes in cardiothoracic surgery

2023年5月7日，临床阶段生物制药公司Renibus Therapeutics宣布在美国胸外科协会（AATS）会议上公布评估RBT-1在接受选择性心脏手术患者中的第二阶段试验的积极最终结果。

RBT-01，由Renibus Therapeutics, Inc. (Renibus Therapeutics, Inc.)公司最早进行研发，目前全球最高研发状态为无进展，治疗领域: 泌尿生殖系统疾病。

2020年5月5日 · RBT-1 represents a new class of crystal protein receptors. RBT-1 is dispensable for Cry5B toxicity against nematodes, consistent with that Cry6A and Cry5B have different nematicidal mechanisms. We also find that Cry6A kills nematodes by complex mechanism since rbt-1 mutation did not affect Cry6A-mediated necrosis signaling pathway.